An Open-Label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-Infected Infants and Children 3 Months to 6 Years of Age.

Trial Profile

An Open-Label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-Infected Infants and Children 3 Months to 6 Years of Age.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Efavirenz (Primary) ; Didanosine; Emtricitabine
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Apr 2016 Results assessing pharmacokinetics of four trials published in the Antimicrobial Agents and Chemotherapy
    • 15 Sep 2015 Results published in the Pediatric Infectious Disease Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top